CORONAVIRUS: CUREVAC AUTHORIZED BY GERMANY TO THE CLINICAL TRIALS ON A VACCINE
FRANKFURT (Reuters) – After BioNTech in April, the start-up German biopharmaceutical CureVac has obtained the authorisation to launch in Germany of clinical trials on an experimental vaccine against the new coronavirus, a-t we learned Tuesday, two sources informed about the file.
The green light of the German authority for the regulation of vaccines, the Paul-Ehrlich-Institut, is expected Wednesday.
Nor CureVac or the Institute did not want to comment.
The world health Organization identifies 11 experimental vaccines against the coronavirus SARS-CoV-2 that are currently undergoing clinical trials on humans.
The German government announced on Monday that it would take a 23% stake in the capital of Curevac, for an investment of about 300 million euros.
The laboratory also plans to introduce in July on the Nasdaq, in the United States, in order to raise funds through a placement of securities.
(Ludwig Burger and Patricia Weiss, French version Jean-Stéphane Brosse)